Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
Triple positive breast cancers overexpress both the human epidermal growth factor receptor 2 (HER2) oncogene and the hormonal receptors (HR) to estrogen and progesterone. These cancers represent a unique therapeutic challenge because of a bidirectional cross-talk between the estrogen receptor alpha...
Saved in:
| Main Authors: | Troy B. Schedin, Virginia F. Borges, Elena Shagisultanova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2018/7835095 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
by: Charlotte K. Kindt, et al.
Published: (2025-01-01) -
Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancer
by: Chenlin Liu, et al.
Published: (2025-01-01) -
OXPHOS inhibition overcomes chemoresistance in triple negative breast cancer
by: Cemile Uslu, et al.
Published: (2025-06-01) -
Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2− metastatic breast cancer: clinical and molecular perspectives
by: Jessé Lopes da Silva, et al.
Published: (2025-07-01) -
HuR inhibition overcomes cFLIP-mediated doxorubicin resistance in triple-negative breast cancer
by: Lanjing Wei, et al.
Published: (2024-12-01)